LBRX - NASDAQ

LB Pharmaceuticals Inc Common Stock

LBRX·NASDAQ

$27.95

+3.4%

HealthcareBiotechnology

Clinical‑stage biopharmaceutical company developing novel therapies for neuropsychiatric diseases (e.g. schizophrenia, bipolar depression). Lead candidate is LB‑102, a methylated derivative of amisulpride.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$801.51M

EPS-1.0000

P/E Ratio-27.95

Earnings Date06/25/2026

lbrx

Cash and Short Term Investments

Last Annual Value

295.21M

3-Year CAGR

140%

5-Year CAGR

69%

10-Year CAGR

30%

Adjust for Inflation

LB Pharmaceuticals Inc Common Stock Competitors Analysis of Cash and Short Term Investments

LBRX · NASDAQ

Company	Cash and Short Term Investments	CAGR 3Y	CAGR 5Y	CAGR 10Y
LB Pharmaceuticals Inc Common Stock NASDAQ:LBRX	295.21M	89.6%	N/A	N/A
Aura Biosciences, Inc. NASDAQ:AURA	144.24M	-13.9%	-0.7%	N/A
Annexon, Inc. NASDAQ:ANNX	238.34M	-2.8%	-0.4%	N/A
Editas Medicine, Inc. NASDAQ:EDIT	146.65M	-23.2%	-21.7%	-2.3%
Humacyte, Inc. NASDAQ:HUMA	50.50M	-14.4%	-25.9%	N/A
Kyverna Therapeutics, Inc. NASDAQ:KYTX	279.25M	69.3%	29.7%	N/A
Lyell Immunopharma, Inc. NASDAQ:LYEL	247.22M	-23.2%	-16.7%	N/A
Replimune Group, Inc. NASDAQ:REPL	483.80M	-6.0%	0.3%	N/A
Tenaya Therapeutics, Inc. NASDAQ:TNYA	100.55M	-1.3%	-16.7%	N/A
Rocket Pharmaceuticals, Inc. NASDAQ:RCKT	188.93M	-20.3%	-13.4%	4.1%
Korro Bio, Inc. NASDAQ:KRRO	75.16M	-23.2%	-10.5%	N/A

LB Pharmaceuticals Inc Common Stock Fair Value Envelope

LBRX · NASDAQ

Our analysis suggests that LBRX has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $27.95, this represents a potential HIDDEN relative to our calculated worth for LB Pharmaceuticals Inc Common Stock.

HIDDEN

Intrinsic Value

Current Price: $27.95

Related Guides

Blog Categories

Continue your LBRX research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.